Protalix BioTherapeutics Inc. (DE) Company Profile
NYSE: PLXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Protalix BioTherapeutics (DE) at a glance
Protalix BioTherapeutics Inc. (DE) (NYSE: PLX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Hackensack, NJ, Israel. Protalix BioTherapeutics (DE) is led by Mr. Dror Bashan and employs about 226 people. At a market capitalization of $244.5 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001006281, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Protalix BioTherapeutics (DE) do?
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
Business description based on the company's public filings.
Company information
- Legal name
- Protalix BioTherapeutics Inc. (DE)
- Ticker
- NYSE: PLX
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Dror Bashan
- Employees
- 226
- Headquarters
- 2 University Plaza, Hackensack, NJ, Israel
- Phone
- 201 696 9345
- Website
- protalix.com
- Market cap
- $244.52M
- SEC CIK
- 0001006281
- Latest annual report
- 10-K · Mar 18, 2026
Companies similar to Protalix BioTherapeutics (DE)
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs PLX |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs PLX |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs PLX |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs PLX |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs PLX |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs PLX |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs PLX |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs PLX |